Novel targeted therapies in diffuse large B-cell lymphoma

Semin Hematol. 2015 Apr;52(2):126-37. doi: 10.1053/j.seminhematol.2015.01.007. Epub 2015 Jan 19.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. Next-generation sequencing techniques have improved our understanding of the molecular pathways that may drive oncogenesis. Many novel classes of drugs are in development that may improve the treatment of DLBCL, either as single agents or in combination, that exploit their synergy to overcome resistance. We review the key novel targets and therapeutics in the treatment of DLBCL, including immunomodulatory agents and immunotherapy.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / metabolism
  • Molecular Targeted Therapy
  • NF-kappa B / metabolism
  • Receptors, Antigen, B-Cell / metabolism
  • Signal Transduction

Substances

  • NF-kappa B
  • Receptors, Antigen, B-Cell